The antithrombotic effect of potent bifunctional thrombin inhibitors based on hirudin sequence, P551 and P532, on He-Ne laser-induced thrombosis in rat mesenteric microvessels

Thrombosis Research

Volumn 90, Issue 5, 1998, Pages 199-206

  Yamashita, Tsutomu ^a,c   Tsuda, Y ^a   Konishi, Y ^b   Okada, Y ^a   Matsuoka, A ^c   Giddings, J C ^d   Yamamoto, J ^a  

^a KOBE GAKUIN UNIVERSITY   (Japan)

^b NATIONAL RESEARCH COUNCIL CANADA   (Canada)

^c HYOGO COLLEGE OF MEDICINE   (Japan)

^d CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Bifunctional thrombin inhibitor; He Ne laser; Hirudin; Platelet; Thrombin; Thrombosis

Indexed keywords

ARGATROBAN; DESULFATOHIRUDIN; HIRUDIN DERIVATIVE; HIRULOG; THROMBIN INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICOAGULATION; ARTERIOLE; ARTICLE; BOLUS INJECTION; CONTROLLED STUDY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MESENTERY BLOOD VESSEL; PRIORITY JOURNAL; RAT; THROMBOGENESIS; THROMBOSIS; VENULE;

ANIMALS; ANTITHROMBINS; HIRUDINS; INJECTIONS, INTRAVENOUS; LASERS; MALE; MESENTERY; MICROCIRCULATION; RATS; RATS, WISTAR; THROMBIN; THROMBOSIS;

EID: 0032104319     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(98)00023-1     Document Type: Article

References (35)

1. 1. Mellott MJ, Connolly TM, York SJ, Bush LR. Prevention of reocclusion by MCI-9038, a thrombin inhibitor, following t-PA-induced thrombolysis in a canine model of femoral arterial thrombosis. Thromb Haemost 1990;64: 526-53.
2. 2. Broersma RJ, Kutcher LW, Heminger EF. The effect of thrombin inhibition in a rat arterial thrombosis model. Thromb Res. 1991;64:405-12.
3. 3. Yamashita T, Yamamoto J, Sasaki Y, Matsuoka A. The antithrombotic effect of low molecular weight synthetic thrombin inhibitors, argatroban and PPACK, on He-Ne laser-induced thrombosis in rat mesenteric microvessels. Thromb Res 1993;69:93-100.
4. 4. Sasaki Y, Morili S, Yamashita T, Yamamoto J. Antithrombotic effect of argatroban on the pial vessels of the rat: A study with He-Ne laser-induced thrombosis formation. Haemostasis 1993;23:104-11.
5. 5. Harker LA, Hanson SR, Runge MS. Thrombin hypothesis of thrombus generation and vascular lesion formation. Am J Cardiol 1995;75: 12B-7B.
6. 6. Rosenberg RD, Rosenberg JS. Natural anticoagulant mechanisms. J Clin Invest 1984;74:1-6.
7. 7. Esmon CT, Esmon NL, Harrir KW. Complex formation between thrombin and thrombomodulin inhibits both thrombin-catalyzed fibrin formation and factor V activation. J Biol Chem. 1982;257:7944-7.
8. 2 in reocclusion following coronary thrombolysis with tissue-type plasminogen activator. Proc Natl Acad Sci USA 1989;86:7585-9.
9. 9. Mirshahi M, Soria J, Soria C, Faivre R, Courtney M, Roitsch C, Tripier D, Caen JP. Evaluation of the inhibition by heparin and hirudin of coagulation activation during r-tPA-induced thrombolysis. Blood 1989;74:1025-30.
10. 2 synthetase and receptors enhances thrombolysis and delays reocclusion in canine coronary arteries. Circulation 1992; 86:1993-9.
11. 11. Hogg PJ, Jackson CM. Fibrin monomer protects thrombin from inactivation by heparin-antithrombin III. Implications for heparin efficacy. Proc Natl Acad Sci USA 1989;86:3619-23.
12. 12. Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 1990;86:385-91.
13. 13. Badimon L, Merino A, Badimon J, Chesebro JH, Fuster V. hirudin and other thrombin inhibitors. Trends Cardiovasc Med 1991;1:261-7.
14. 14. Rydel TJ, Ravichandran KG, Tulinsky A, Bode W, Huber R, Roitsch C, Fenton, JW II. The structure of a complex of recombinant hirudin and human α-thrombin. Science 1990;249: 277-80.
15. 15. Imura Y, Stassen JM, Collen D. Comparative antithrombotic effects of heparin, recombinant hirudin and argatroban in a hamster femoral vein platelet-rich mural thrombosis model. J Pharmacol Exp Ther 1992;261:895-8.
16. 16. Markward F, Nowak G, Sturzebecher J, Grie SS, Bach U, Walsmann, P, Volgel G. Pharmacokinetics and anticoagulant effect of hirudin in man. Thromb Haemost 1984;52:160-3.
17. 17. Stone SR, Hofsteenge J. Kinetics of the inhibition of thrombin by hirudin. Biochemistry 1986;25: 4622-8.
18. 18. Tsuda Y, Cygler M, Gibbs BF, Pedyczak A, Fethiere J, Yue SY, Konishi Y. Design of potent bivalent thrombin inhibitors based on hirudin sequence: Incorporation of non-substrate-type active site inhibitors. Biochemistry 1994;33: 14443-51.
19. 19. Witting JI, Bourdon P, Brezniak DV, Maraganore JM, Fenton JW 2d. Thrombin-specific inhibition by and slow cleavage of hirulog-1. Biochem. J 1992;283:737-43.
20. 20. Dimaio J, Gibbs B, Lefebvre J, Konishi Y, Munn D, Yue SY, Hornberger W. Synthesis of a homologous series of ketomethylene arginyl pseudodipeptidea and application to low molecular weight hirudin-like thrombin inhibitors. J Med Chem 1992;35:3331-41.
21. 21. Yamamoto J, Iizumi H, Hirota R, Shimonaka K, Nagamatsu Y, Horie N, Morita S. Effect of physical training on thrombotic tendency in rats: Decrease in thrombotic tendency measured by the He-Ne laser-induced thrombus formation method. Haemostasis 1989;19:260-5.
22. 22. Kovacs IB, Tigy-Sebes A, Trombitas K, Gorog P. Evans Blue: An ideal energy-absorbing material to produce intravascular microinjury by He-Ne gas laser. Microvasc Res 1975;10: 107-24.
23. 23. Sharma GVRK, Lapsley D, Vita JA, Sharma S, Coccio E, Adelman B, Loscalzo J. Usefulness and tolerability of hirulog, a direct thrombin-inhibitor, in unstable angina pectoris. Am J Cardiol 1993;72:1357-60.
24. 24. Lindahl, AK, Scarborough RM, Naughton MA, Harker LA, Hanson SR. Antithrombotic effect of a thrombin receptor antagonist peptide in baboons (Abstract). Thromb Haemostas 1993;69:1196.
25. 25. Tanabe K, Hara T, Morishima Y, Ishihara H, Yokoyama A, Honda, Y, Iwamoto M. An orally active, specific inhibitor of factor Xa prevents thrombosis without affecting bleeding time in rats. Thromb Haemostas 1993;69: (Suppl)890.
26. 26. Kelly AB, Hanson SR, Dunwiddie CT, Harker LA. Safe lasting interruption of arterial thrombosis by transient intravenous administration of tick anticoagulant peptide TAP (Abstract). Circulation 1992;86:(Suppl 1)I-411.
27. 27. Yamashita T, Matsuoka A, Funatsu A, Yamamoto J. The antithrombotic effect of human activated protein C on He-Ne laser-induced thrombosis in rat mesenteric microvessels. Thromb Res 1994;75:33-40.
28. 28. Lindahl AK, Wildgoose P, Lumsden AB, Allen R, Kelly AB, Harker LA, Hanson SR. Active site-inhibited factor VIIa blocks tissue factor activity and prevents arterial thrombus formation in baboons (Abstract). Circulation 1993; 88:(Suppl)I-417.
29. 29. Yamamoto J, Ishii I, Okita N, Sasaki Y, Yamashita T, Matsuoka A, Muraki T, Giddings JC, Watanabe S, Seki J. The differential involvement of von Willebrand factor, fibronectin in acute experimental thrombosis in rat cerebral and mesenteric microvessels. Jpn J Physiol 1997;47:431-41.
30. 30. Povlishok JT, Rosenblum WI. Injury of brain microvessels with a helium-neon laser and Evans Blue can elicit local platelet aggregation without endothelial denudation. Arch Pathol Lab Med 1987;111:415-21.
31. 31. Tracy PB, Nesheim NE, Mam KG. Coordinate binding of factor Va and factor Xa to the unstimulated platelet. J Biol Chem 1981;256: 743-51.
32. 32. Awbrey BJ, Hoak JC, Owen WG. Binding of human thrombin to cultured human endothelial cells. J Biol Chem 1979;254:4092-5.
33. 33. Tiruppathi C, Lum H, Andersen TT, Fenton JW, Malik AB. Thrombin receptor 14-amino acid peptide binds to endothelial cell and stimulates calcium transients. Am J Physiol 1992; 263:595-601.
34. 2-((3-methyl-1,2,3,4-tetrahydro-8-quinolinyl) sulfonyl)-L-arginyl))-piperidine-carboxylicacid. Biochemistry 1984;23:85-90.
35. 35. Salveson G, Pizzo SV. Proteinase inhibitors: α-macroglobulins, serpins and kunins. In: Salzman RW, Editor. Hemostasis and Thrombosis. Basic Principles and Clinical Practice. Philadelphia: J.B. Lippincott Co; p. 241-58. 1994.